Description
Retatrutide, identified in early research as LY3437943, is a peptide studied for activity at three receptor systems: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors. Its research profile connects multi-receptor pharmacology with metabolic signalling. This 20mg listing is a separate catalogue quantity from the existing lower-strength entries.
Mechanism & Research Background
The compound’s triple-agonist design allows researchers to examine interactions with three related but distinct hormone receptors. Discovery studies and structural research have investigated receptor activation and binding interactions. This differs from the single GLP-1 receptor emphasis of semaglutide and the dual GIP/GLP-1 profile of tirzepatide.
Areas of Research
- Comparative activation of GIP, GLP-1 and glucagon receptors.
- Structural interactions between peptide ligands and their target receptors.
- Multi-receptor signalling within defined metabolic research models.
Comparisons between single-, dual- and triple-receptor compounds require matched assay conditions and suitable controls. Published results depend on the material, model and endpoints used; they are not a prediction of weight loss or other outcomes from this catalogue product. The 20mg label describes the listed quantity, not a prepared solution concentration or an administration instruction.
Product Details
- Product: Retatrutide 20mg
- Listed quantity: 20mg
- Compound class: GIP, GLP-1 and glucagon receptor agonist peptide
- Product code: RT20
Storage & Handling
Follow the storage conditions and handling guidance in the applicable supplier documentation. Protect the material from unsuitable heat, light and moisture, and record the batch used in each experiment. Preparation and storage requirements depend on the supplied formulation and the research method.
Batch Documentation
Certificates of analysis should be matched to the product and batch. Consult the relevant report for measured identity, content and purity; a purity result alone does not establish sterility or endotoxin status.
Research References
Important Notice
Premium research peptides synthesised and shipped from Australia. For in-vitro research purposes only. Strictly not for human or veterinary consumption. All products supplied are strictly for laboratory research and development. This information describes the compound’s research background and does not provide dosing instructions or claim a therapeutic benefit.
Reviews
There are no reviews yet.